-
公开(公告)号:NO991132D0
公开(公告)日:1999-03-09
申请号:NO991132
申请日:1999-03-09
Applicant: BASF AG
Inventor: STEINER GERD , LUBISCH WILFRIED , BACH ALFRED , EMLING FRANZ , WICKE KARSTEN , TESCHENDORF HANS-JUERGEN , BEHL BERTHOLD , KERRIGAN FRANK , CHEETHAM SHARON
IPC: A61K31/435 , A61K31/519 , A61P25/24 , A61P43/00 , C07D211/00 , C07D239/00 , C07D333/00 , C07D495/14 , C07D221/00
Abstract: A 3-substituted 3,4,5,6,7,8-hexahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidine compound of formula IwhereinR1 is hydrogen, C1-C4-alkyl, acetyl or benzoyl, optionally substituted phenyl-C1-C4-alkyl, naphthyl-C1-C3-alkyl, phenyl-C2-C3-alkanone or a phenylcarbamoyl-C2-alkyl,R2 is optionally substituted phenyl, pyridyl, pyrimidyl or pyrazinyl, or an optionally substituted bicyclus wherein one of the two fused rings is a phenyl, a pyridyl, a pyrimidyl or a pyrazinyl ring,A is NH or oxygen,B is hydrogen or methyl,C is hydrogen, methyl or hydroxyl,X is nitrogen,Y is CH2, CH2-C2, CH2-C2-CH2 or CH2-CH,Z is nitrogen, C or CH, and the linkage between Y and Z is a single or a double bond, andn is 2, 3 or 4,or a physiologically tolerated salt thereof, and compositions comprising them and their use as antagonists of 5HT1B and 5HT1A and for the treatment of depression and related disorders.
-
公开(公告)号:HUT77608A
公开(公告)日:1998-06-29
申请号:HU9700111
申请日:1995-07-14
Applicant: BASF AG
Inventor: BACH ALFRED , HELLENDAHL BEATE , LANSKY ANNEGRET , RENDENBACH-MUELLER BEATRICE , TESCHENDORF HANS-JUERGEN , UNGER LILIANE , WICKE KARSTEN
IPC: C07D233/84 , A61K31/33 , A61K31/415 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61K31/4425 , A61K31/445 , A61K31/495 , A61K31/496 , A61P25/18 , A61P25/20 , A61P25/24 , A61P25/26 , C07D213/56 , C07D213/64 , C07D213/65 , C07D213/70 , C07D213/73 , C07D213/79 , C07D213/81 , C07D233/90 , C07D307/79 , C07D333/24 , C07D333/28 , C07D333/38 , C07D471/18 , A61K31/505 , A61K31/52 , A61K31/53
Abstract: PCT No. PCT/EP95/02782 Sec. 371 Date Jan. 14, 1997 Sec. 102(e) Date Jan. 14, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02246 PCT Pub. Date Feb. 1, 1996The present invention relate to the use of heterocyclic compounds of the following formula:Het-A-B-Arwhere Het, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
-
公开(公告)号:MX9700429A
公开(公告)日:1998-05-31
申请号:MX9700429
申请日:1995-07-14
Applicant: BASF AG
Inventor: HELLENDAHL BEATE , LANSKY ANNEGRET , RENDENBACH-MULLER BEATRICE , BACH ALFRED , UNGER LILIANE , TESCHENDORF HANS-JURGEN , WICKE KARSTEN
IPC: C07D277/22 , A61K31/425 , A61K31/426 , A61K31/433 , A61K31/435 , A61K31/44 , A61K31/4439 , A61K31/445 , A61K31/454 , A61K31/496 , A61K31/54 , C07D277/20 , C07D277/32 , C07D277/36 , C07D277/42 , C07D285/12 , C07D285/125 , C07D285/135 , C07D417/12
Abstract: La presente invencion se refiere al uso de compuestos de tiazol y tiadiazol de la siguiente formula: donde R1, A, B y Ar tienen los significados establecidos en la descripcion. Los compuestos de conformidad con la presente invencion tiene una afinidad elevada para el receptor D3 de dopamina y pueden por consiguiente emplearse para tratar trastornos del sistema nervioso central.
-
公开(公告)号:BR9508296A
公开(公告)日:1998-05-19
申请号:BR9508296
申请日:1995-07-14
Applicant: BASF AG
Inventor: HELLENDAHL BEATE , RENDENDACH-MULLER BEATRICE , LANSKY ANNEGRET , WICKE CARSTEN , TESCHENDORF HANS-JUERGEN , BACH ALFRED , UNGER LILIANE
IPC: C07D233/84 , A61K31/33 , A61K31/415 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61K31/4425 , A61K31/445 , A61K31/495 , A61K31/496 , A61P25/18 , A61P25/20 , A61P25/24 , A61P25/26 , C07D213/56 , C07D213/64 , C07D213/65 , C07D213/70 , C07D213/73 , C07D213/79 , C07D213/81 , C07D233/90 , C07D307/79 , C07D333/24 , C07D333/28 , C07D333/38 , C07D471/18
Abstract: PCT No. PCT/EP95/02782 Sec. 371 Date Jan. 14, 1997 Sec. 102(e) Date Jan. 14, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02246 PCT Pub. Date Feb. 1, 1996The present invention relate to the use of heterocyclic compounds of the following formula:Het-A-B-Arwhere Het, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
-
85.
公开(公告)号:AU4207197A
公开(公告)日:1998-04-02
申请号:AU4207197
申请日:1997-08-22
Applicant: BASF AG
Inventor: STEINER GERD , LUBISCH WILFRIED , BACH ALFRED , EMLING FRANZ , WICKE KARSTEN , TESCHENDORF HANS-JURGEN , BEHL BERTHOLD , KERRRIGAN FRANK , CHEETHAM SHARON
IPC: A61K31/435 , A61K31/519 , A61P25/24 , A61P43/00 , C07D211/00 , C07D239/00 , C07D333/00 , C07D495/14
Abstract: A 3-substituted 3,4,5,6,7,8-hexahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidine compound of formula IwhereinR1 is hydrogen, C1-C4-alkyl, acetyl or benzoyl, optionally substituted phenyl-C1-C4-alkyl, naphthyl-C1-C3-alkyl, phenyl-C2-C3-alkanone or a phenylcarbamoyl-C2-alkyl,R2 is optionally substituted phenyl, pyridyl, pyrimidyl or pyrazinyl, or an optionally substituted bicyclus wherein one of the two fused rings is a phenyl, a pyridyl, a pyrimidyl or a pyrazinyl ring,A is NH or oxygen,B is hydrogen or methyl,C is hydrogen, methyl or hydroxyl,X is nitrogen,Y is CH2, CH2-C2, CH2-C2-CH2 or CH2-CH,Z is nitrogen, C or CH, and the linkage between Y and Z is a single or a double bond, andn is 2, 3 or 4,or a physiologically tolerated salt thereof, and compositions comprising them and their use as antagonists of 5HT1B and 5HT1A and for the treatment of depression and related disorders.
-
公开(公告)号:ID18260A
公开(公告)日:1998-03-19
申请号:ID973146
申请日:1997-09-10
Applicant: BASF AG
Inventor: STEINER GERD , LUBISCH WILFRIED , BACH ALFRED , EMLING FRANZ , WICKE KARSTEN , TESCHENDORF HANS-JURGEN , BEHL BERTHOLD , CHEETHAM SHARON , KERRIGAN FRANK
IPC: A61K31/435 , A61K31/519 , A61P25/24 , A61P43/00 , C07D211/00 , C07D239/00 , C07D333/00 , C07D495/14
Abstract: A 3-substituted 3,4,5,6,7,8-hexahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidine compound of formula IwhereinR1 is hydrogen, C1-C4-alkyl, acetyl or benzoyl, optionally substituted phenyl-C1-C4-alkyl, naphthyl-C1-C3-alkyl, phenyl-C2-C3-alkanone or a phenylcarbamoyl-C2-alkyl,R2 is optionally substituted phenyl, pyridyl, pyrimidyl or pyrazinyl, or an optionally substituted bicyclus wherein one of the two fused rings is a phenyl, a pyridyl, a pyrimidyl or a pyrazinyl ring,A is NH or oxygen,B is hydrogen or methyl,C is hydrogen, methyl or hydroxyl,X is nitrogen,Y is CH2, CH2-C2, CH2-C2-CH2 or CH2-CH,Z is nitrogen, C or CH, and the linkage between Y and Z is a single or a double bond, andn is 2, 3 or 4,or a physiologically tolerated salt thereof, and compositions comprising them and their use as antagonists of 5HT1B and 5HT1A and for the treatment of depression and related disorders.
-
公开(公告)号:SI9520084A
公开(公告)日:1997-08-31
申请号:SI9520084
申请日:1995-07-14
Applicant: BASF AG
Inventor: HELLENDAHL BEATE , LANSKY ANNEGERET , BACH ALFRED , RENDENBACH-MUELLER BEATRICE , UNGER LILIANE , WICKE CARSTEN , TESCHENDORF HANS-JURGEN
IPC: A61K31/33 , A61K31/415 , A61K31/44 , C07D233/84 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61K31/4425 , A61K31/445 , A61K31/495 , A61K31/496 , A61P25/18 , A61P25/20 , A61P25/24 , A61P25/26 , C07D213/56 , C07D213/64 , C07D213/65 , C07D213/70 , C07D213/73 , C07D213/79 , C07D213/81 , C07D233/90 , C07D307/79 , C07D333/24 , C07D333/28 , C07D333/38 , C07D471/18
Abstract: PCT No. PCT/EP95/02782 Sec. 371 Date Jan. 14, 1997 Sec. 102(e) Date Jan. 14, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02246 PCT Pub. Date Feb. 1, 1996The present invention relate to the use of heterocyclic compounds of the following formula:Het-A-B-Arwhere Het, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
-
公开(公告)号:CZ9697A3
公开(公告)日:1997-08-13
申请号:CZ9697
申请日:1995-07-14
Applicant: BASF AG
Inventor: HELLENDAHL BEATE , LANSKY ANNEGRET , RENDENBACH-MULLER BEATRICE , BACH ALFRED , UNGER LILIANE , TESCHENDORF HANS-JURGEN , WICKE CARSTEN
IPC: C07D233/84 , A61K31/33 , A61K31/415 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61K31/4425 , A61K31/445 , A61K31/495 , A61K31/496 , A61P25/18 , A61P25/20 , A61P25/24 , A61P25/26 , C07D213/56 , C07D213/64 , C07D213/65 , C07D213/70 , C07D213/73 , C07D213/79 , C07D213/81 , C07D233/90 , C07D307/79 , C07D333/24 , C07D333/28 , C07D333/38 , C07D471/18
Abstract: PCT No. PCT/EP95/02782 Sec. 371 Date Jan. 14, 1997 Sec. 102(e) Date Jan. 14, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02246 PCT Pub. Date Feb. 1, 1996The present invention relate to the use of heterocyclic compounds of the following formula:Het-A-B-Arwhere Het, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
-
公开(公告)号:NO970164L
公开(公告)日:1997-03-14
申请号:NO970164
申请日:1997-01-14
Applicant: BASF AG
Inventor: HELLENDAHL BEATE , LANSKY ANNEGRET , RENDENBACH-MUELLER BEATRICE , BACH ALFRED , UNGER LILIANE , TESCHENDORF HANS-JUERGEN , WICKE KARSTEN
IPC: C07D277/22 , A61K31/425 , A61K31/426 , A61K31/433 , A61K31/435 , A61K31/44 , A61K31/4439 , A61K31/445 , A61K31/454 , A61K31/496 , A61K31/54 , C07D277/20 , C07D277/32 , C07D277/36 , C07D277/42 , C07D285/12 , C07D285/125 , C07D285/135 , C07D417/12 , A61K31/495 , A61K31/41
Abstract: PCT No. PCT/EP95/02783 Sec. 371 Date Jan. 14, 1997 Sec. 102(e) Date Jan. 14, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02249 PCT Pub. Date Feb. 1, 1996The present invention relates to the use of thiazole and thiadiazole compounds of the following formula: where R1, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders of the central nervous system.
-
公开(公告)号:FI970148A
公开(公告)日:1997-01-14
申请号:FI970148
申请日:1997-01-14
Applicant: BASF AG
Inventor: HELLENDAHL BEATE , LANSKY ANNEGRET , RENDENBACH-MUELLER BEATRICE , BACH ALFRED , UNGER LILIANE , TESCHENDORF HANS-JUERGEN , WICKE KARSTEN
IPC: C07D233/84 , A61K31/33 , A61K31/415 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61K31/4425 , A61K31/445 , A61K31/495 , A61K31/496 , A61P25/18 , A61P25/20 , A61P25/24 , A61P25/26 , C07D213/56 , C07D213/64 , C07D213/65 , C07D213/70 , C07D213/73 , C07D213/79 , C07D213/81 , C07D233/90 , C07D307/79 , C07D333/24 , C07D333/28 , C07D333/38 , C07D471/18 , A61K
Abstract: PCT No. PCT/EP95/02782 Sec. 371 Date Jan. 14, 1997 Sec. 102(e) Date Jan. 14, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02246 PCT Pub. Date Feb. 1, 1996The present invention relate to the use of heterocyclic compounds of the following formula:Het-A-B-Arwhere Het, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
-
-
-
-
-
-
-
-
-